

# Electric muscle stimulation for treatment of functional shoulder instability

<b>Submission date</b> 25/03/2019	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 05/04/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 03/05/2024	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Functional posterior shoulder instability (FPSI) is a force imbalance of stabilizing shoulder muscles which mainly affects teenagers and young adults with severe effects on shoulder function. Patients with FPSI suffer from repetitive posterior displacements every time the shoulder passes a particular phase of movement in the mid-range of motion. Severely restricted shoulder function and symptoms such as pain, loss of range of motion due to weakness or blockage that inhibits any further movement, as well as a strong feeling of instability, are reported by the affected patients. Current therapy includes conservative as well as surgical stabilization attempts. In daily clinical practice, however, standard physiotherapy is often ineffective and after years of unsuccessful conservative treatment, patients affected with FPSI finally undergo a surgical stabilization attempt with results that are often worse than before. In a study with 5 participating centres, a promising therapy concept based on electric muscle stimulation shall be compared to the current standard care physiotherapy. If the results of the new treatment approach show better results than the existing standard physiotherapy, a much-needed step forward in the treatment of patients with FPSI will be achieved and likely lead to a complete change in the existing therapy for this challenging pathology. For the patients themselves, this new treatment concept possibly could represent a true „game-changer“ that might free them of the burden of FPSI.

### Who can participate?

Participants over the age of 14 with FPSI will be included in this study irrespective of gender or duration of symptoms. Exclusion criteria focus on structural pathologies (static posterior migration, connective tissue diseases, degenerative joint diseases, structural defects) and other pathologies (multidirectional instability, neurological disorder or nerve injuries, existing pain syndrome, medical contraindication to EMS treatment) hindering, impeding, or prohibiting to complete the control or experimental treatment. Additionally, participants with previous participation in a pathology-targeted standardized EMS or physiotherapy protocol are excluded in order to avoid potential unwillingness to participate in or preformed mindset towards an intervention that they previously tried already without success.

### What does the study involve?

The study will compare two treatment groups. The experimental intervention consists of an EMS-

based training protocol to stimulate specific muscle groups of the shoulder. The training involves a combination of certain exercises with increasing difficulty and intensity. The control intervention includes a pathology-targeted standardized physiotherapy protocol which has been developed and agreed on by international renowned shoulder experts. Both experimental and control treatment will include 18 one-hour trainings evenly distributed over a time period of 6 weeks and will be performed by the same physiotherapist at each participating centre based on standardized protocols. In the case of subjectively unsatisfying results, an optional switch (cross-over) into the other treatment group is allowed to make both potentially superior therapies available to all participants within a reasonable time (3 months after the beginning/6 weeks after the end of the intervention).

What are the possible benefits and risks of participating?

Each participant benefits by receiving an intensive, targeted and potentially equal physiotherapeutic treatment concept. The training concepts aim to increase endurance and coordination including functional training as well as strengthen specific stabilizing shoulder muscles. In addition, as part of clinical routine, each participant will receive a clinical evaluation and individualized consultation on the likelihood of reoccurring shoulder displacements. No adverse events or complications of the experimental EMS-based therapy have been observed in a pilot study.

Where is the study run from?

This study will be available in centres across Germany and Switzerland and supervised by the Charité- Universitätsmedizin Berlin as lead centre. Further centres include the ATOS Clinic, Munich, Germany; the Annastift Hospital, Hannover, Germany; the St. Vincentius Kliniken, Karlsruhe, Germany; Schoen Clinic Düsseldorf and University Clinic Düsseldorf, Germany; and the Schulthess Clinic, Zurich, Switzerland.

When is the study starting and how long is it expected to run for?

June 2019 to June 2022

Who is funding the study?

This project is currently initiated and funded by the investigators

Who is the main contact?

PD Dr. med. univ. Philipp Moroder  
philipp.moroder@charite.de

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Philipp Moroder

**Contact details**

Department of Shoulder and Elbow Surgery  
Center for Musculoskeletal Surgery- Campus Virchow  
Charité Universitätsmedizin  
Augustenburgerplatz 1  
Berlin

Germany  
13353  
+4930450652175  
philipp.moroder@charite.de

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

Nil known

## **Study information**

### **Scientific Title**

Electric muscle stimulation for treatment of non-controllable positional functional posterior shoulder instability

### **Acronym**

EMS for FPSI

### **Study objectives**

Electrical muscle stimulation (EMS) based therapy has the same clinical effect as conventional state-of-the art physiotherapy treatment for FPSI.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 30/08/2018, Ethics Committee of Charité – Universitätsmedizin Berlin (Charitéplatz 1, Virchowweg 10, 10117 Berlin; +49 (0)30 450 517 222; ethikkommission@charite.de), ref: EA2 /077/18

### **Study design**

Multi-centric randomized controlled therapeutic trial active control no masking optional cross-over design

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Non-controllable positional functional posterior shoulder instability (FPSI).

## **Interventions**

In a multicentric prospective randomized controlled trial, we would like to objectively assess a promising new EMS-based treatment concept which was evaluated at our institution in a prospective pilot trial involving 24 cases with previously unsuccessful conventional physiotherapy treatment of FPSI. Pathology-targeted physiotherapy is the current standard treatment of FPSI and will serve as the control intervention in the proposed trial. All involved centers as well as independent experts have specified and agreed on a standardized exercise protocol for the control intervention during a Delphi survey. The control intervention will have the same duration, intervals, and instructing physiotherapist (at each center) as the experimental intervention. An optional bi-directional cross-over into the other intervention group (experimental or control) is possible after follow-up examination at the time-point T2 (3 months after the beginning/6 weeks after the end of the intervention) in the case of subjectively unsatisfying results despite completion of the originally assigned intervention to offer both possibly superior interventions to all participants.

Experimental intervention: electrical muscle stimulation based therapy protocol

Control intervention: conventional state-of-the art physiotherapy protocol

Follow-up per patient: 0 weeks (T0), 6 weeks (T1), 3 months (T2), 6 months (T3), 12 months (T4)

Duration of intervention per patient: 6 weeks

The strict inclusion and exclusion criteria create a homogeneous group of study participants. After a patient has decided to enter the study and provided written informed consent, he/she will be randomized in one of the two treatment groups (allocation ratio 1:1). A randomization sequence will be generated electronically using Stata (StataCorp LP, Texas USA) separately for each participating center and loaded within an online study database in REDCap<sup>17</sup> (Research Electronic Data Capture) for automatic concealed allocation. Block-randomization with blocks of 2 and 4 will be used to minimize the risk of unequal group sizes. The randomization process allows to divide the study participants into two cohorts of comparable characteristics. We will compare these cohorts with regards to potential confounding factors before the outcome analyses and adjust statistically for any observed imbalance as appropriate.

Since the main outcome measurement is a subjective score, blinding of the examiner is not necessary. Blinding of the patients themselves is not possible due to the nature of experimental and control intervention. This circumstance can potentially introduce a confirmation bias from the patients' side. However, according to the trial design, all patients with previous participation in a pathology-targeted standardized EMS or physiotherapy protocol are excluded which reduces the risk for a pre-conditioned mindset in patients.

## **Intervention Type**

Procedure/Surgery

## **Primary outcome(s)**

Western Ontario Shoulder Instability Index (WOSI) at T2

## **Key secondary outcome(s))**

1. WOSI at T1, T3, and T4.

At 0 weeks (T0), 6 weeks (T1), 3 months (T2), 6 months (T3), 12 months (T4):

2. Subjective shoulder value

3. Impairment of daily activities

4. Sports impairment

5. Pain level

6. Range of motion
7. Strength
8. Satisfaction with treatment

Assessment of safety: Based on the complication-free pilot trial, no adverse events are pre-specified but continuous recording of unexpected adverse events will be executed in both treatment arms.

**Completion date**

01/06/2022

## Eligibility

**Key inclusion criteria**

1. Non-controllable positional functional posterior shoulder instability (FPSI)
2. Aged 13 years or over

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

13 years

**Sex**

All

**Total final enrolment**

59

**Key exclusion criteria**

1. Multidirectional instability
2. Static posterior instability/migration
3. Connective tissue disease
4. Degenerative joint disease
5. Structural defects visible on pre-treatment MRI
6. Neurological disorder or nerve injury
7. Existing pain syndrome (defined by pain at rest or during motion, which is not caused by dislocation but impedes physiotherapeutic training and/or EMS)
8. Non-tolerance of EMS treatment (e.g. cardiac pacemaker)
9. Previous participation in a pathology-specific standardized EMS or physiotherapy protocol

Added 21/02/2020:

5. Structural defects visible on pre-treatment MRI:
  - 5.1. Any acquired glenoid bone defect

- 5.2. Glenoid dysplasia with more than 10° of retroversion (of cartilaginous surface) according to Imhoff et al.
- 5.3. Convex cartilaginous glenoid articular surface
- 5.4. Static posterior glenohumeral decentering >55% according to Walch et al.
- 5.5. Degenerative changes (any visible cartilage damage or OA)

**Date of first enrolment**

01/06/2019

**Date of final enrolment**

01/01/2022

## **Locations**

**Countries of recruitment**

Germany

Switzerland

**Study participating centre**

**Charité University Hospital**

Centrum für Muskuloskeletale Chirurgie

Augustenburger Platz 1

Berlin

Germany

13353

**Study participating centre**

**Annastift Hospital**

Anna-von-Borries-Straße 1-7

Hanover

Germany

30625

**Study participating centre**

**ATOS Clinic**

Effnerstraße 38

Munich

Germany

81925

**Study participating centre**

**St. Vincentius Clinic**  
Südendstr. 32  
Karlsruhe  
Germany  
76135

**Study participating centre**  
**Schulthess Clinic**  
Lengghalde 2  
Zurich  
Switzerland  
8008

**Study participating centre**  
**Schoen Clinic Düsseldorf**  
Am Heerdter Krankenhaus 2  
Düsseldorf  
Germany  
40549

**Study participating centre**  
**University Clinic Düsseldorf**  
Moorenstraße 5  
Düsseldorf  
Germany  
40225

## **Sponsor information**

**Organisation**  
Charité - Universitätsmedizin Berlin

**ROR**  
<https://ror.org/001w7jn25>

## **Funder(s)**

**Funder type**  
Research organisation

**Funder Name**  
Deutsche Forschungsgemeinschaft

**Alternative Name(s)**  
German Research Association, German Research Foundation, Deutsche Forschungsgemeinschaft (DFG), DFG

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
Germany

## Results and Publications

**Individual participant data (IPD) sharing plan**  
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

**IPD sharing plan summary**  
Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/01/2024	03/05/2024	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Protocol file</a>	version v1.0	30/11/2019	02/12/2019	No	No
<a href="#">Protocol file</a>	version v2.0	18/02/2020	18/02/2020	No	No
<a href="#">Protocol file</a>	version v3.0	25/03/2020	25/03/2020	No	No
<a href="#">Protocol file</a>	version v4.0	08/04/2020	04/06/2020	No	No